Holen Sie sich die Stockscreener-App
14.07
35.94%
-7.895
Handel nachbörslich:
13.37
-0.705
-5.01%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SRPT?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$21.97
Offen:
$16.975
24-Stunden-Volumen:
76.62M
Relative Volume:
11.49
Marktkapitalisierung:
$1.38B
Einnahmen:
$2.23B
Nettoeinkommen (Verlust:
$-248.39M
KGV:
-5.2323
EPS:
-2.69
Netto-Cashflow:
$-697.55M
1W Leistung:
-22.54%
1M Leistung:
-32.23%
6M Leistung:
-88.07%
1J Leistung:
-90.21%
1-Tages-Spanne:
$12.81
$19.18
1-Wochen-Bereich:
$12.81
$22.86
52-Wochen-Spanne:
$12.81
$150.48
Sarepta Therapeutics Inc Stock (SRPT) Company Profile
Firmenname
Sarepta Therapeutics Inc
Sektor
Branche
Telefon
617-274-4000
Adresse
215 FIRST STREET, CAMBRIDGE, MA
Vergleichen Sie SRPT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SRPT
Sarepta Therapeutics Inc
|
14.07 | 1.79B | 2.23B | -248.39M | -697.55M | -2.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.81 | 120.40B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
542.52 | 61.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.53 | 41.06B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
564.59 | 34.29B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.55 | 27.09B | 3.81B | -644.79M | -669.77M | -6.24 |
Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-18 | Herabstufung | Needham | Buy → Hold |
| 2025-06-20 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-06-18 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-06-17 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-06-16 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2025-06-16 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-06-16 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-06-16 | Herabstufung | H.C. Wainwright | Neutral → Sell |
| 2025-06-16 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-06-16 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-06-06 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2025-05-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2025-04-11 | Eingeleitet | Wells Fargo | Overweight |
| 2025-04-02 | Hochstufung | H.C. Wainwright | Sell → Neutral |
| 2025-03-31 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Hold |
| 2024-11-27 | Bestätigt | Needham | Buy |
| 2024-11-25 | Eingeleitet | H.C. Wainwright | Sell |
| 2024-11-07 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2024-10-21 | Eingeleitet | Jefferies | Buy |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-07-29 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-06-26 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-05-31 | Eingeleitet | Piper Sandler | Overweight |
| 2024-05-28 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-05-14 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-01-31 | Eingeleitet | BMO Capital Markets | Outperform |
| 2023-12-13 | Fortgesetzt | Citigroup | Buy |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-11-21 | Eingeleitet | Wedbush | Outperform |
| 2023-10-31 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-31 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-06-23 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-04-26 | Eingeleitet | SMBC Nikko | Outperform |
| 2023-04-04 | Eingeleitet | Citigroup | Buy |
| 2023-03-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-12-22 | Bestätigt | BTIG Research | Buy |
| 2022-12-16 | Hochstufung | UBS | Neutral → Buy |
| 2022-04-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2022-01-05 | Bestätigt | Needham | Buy |
| 2021-12-09 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-11-05 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-09-15 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-08-05 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-01-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-01-11 | Herabstufung | UBS | Buy → Neutral |
| 2021-01-08 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2021-01-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-01-08 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | Eingeleitet | Berenberg | Hold |
| 2020-10-28 | Eingeleitet | UBS | Buy |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-08-20 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2020-03-31 | Eingeleitet | Mizuho | Buy |
| 2019-11-01 | Eingeleitet | Guggenheim | Buy |
| 2019-08-21 | Bestätigt | Needham | Buy |
| 2019-07-09 | Bestätigt | Morgan Stanley | Overweight |
| 2019-07-01 | Bestätigt | RBC Capital Mkts | Outperform |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-11 | Bestätigt | Credit Suisse | Outperform |
| 2018-10-12 | Eingeleitet | Bernstein | Outperform |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-26 | Bestätigt | RBC Capital Mkts | Outperform |
| 2018-09-14 | Fortgesetzt | BofA/Merrill | Buy |
| 2018-09-06 | Eingeleitet | Credit Suisse | Outperform |
| 2018-08-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-06-21 | Bestätigt | Robert W. Baird | Outperform |
| 2018-06-20 | Bestätigt | Needham | Buy |
| 2018-06-19 | Bestätigt | H.C. Wainwright | Buy |
Alle ansehen
Sarepta Therapeutics Inc Aktie (SRPT) Neueste Nachrichten
This Gene Therapy Maker Refuses to Halt Shipments After Patient Deaths - Men's Journal
What drives Sarepta Therapeutics Inc. stock priceAccelerated wealth expansion - Autocar Professional
Sarepta Therapeutics Announces Layoff of 493 Employees, Including 80 in Ohio, Amid FDA Scrutiny and Stock Decline - Hoodline
Gene therapy maker Sarepta tells FDA it won’t halt shipments despite patient deaths - WTOP
Gene therapy maker Sarepta tells FDA it won't halt shipments despite patient deaths - Yahoo Finance
Gene Therapy Maker Sarepta Tells FDA It Won't Halt Shipments Despite Patient Deaths - U.S. News & World Report
Sarepta Therapeutics lays off 500 employees amid FDA investigation, including 80 in Columbus - nbc4i.com
Sarepta plans Elevidys shipments despite FDA request (SRPT) - Seeking Alpha
Securities Fraud Litigation and Shareholder Returns: A Strategic Evaluation of Sarepta Therapeutics' ELEVIDYS Case - AInvest
M&T Bank Corp Reduces Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - Defense World
Sarepta Therapeutics: A Sell Signal Amid Safety Crises and Existential Risks - AInvest
Sarepta Therapeutics (NASDAQ:SRPT) Shares Gap Down Following Analyst Downgrade - Defense World
Sarepta Therapeutics Inc. Stock Analysis and ForecastExceptional stock performance - Jammu Links News
Sarepta Therapeutics (NASDAQ:SRPT) Reaches New 52-Week Low Following Analyst Downgrade - Defense World
Sarepta Therapeutics laying off nearly 500 employees, including 80 in Franklin County - 10TV
Sarepta CEO: ‘We Have, I Believe, a Very Laudable History of Being Extraordinarily Transparent’ - MedCity News
SRPT BREAKING NEWS: Sarepta Therapeutics, Inc. - GlobeNewswire
Exclusive: Sarepta says it won't comply with FDA request to stop shipping gene therapy Elevidys - Reuters
Is Sarepta Therapeutics Inc. a good long term investmentOutstanding capital growth - Jammu Links News
Securities Fraud Class Action Filed Against Sarepta Therapeutics, Inc. (SRPT)Levi & Korsinsky Reminds Investors of August 25, 2025 - ACCESS Newswire
Sarepta receives FDA request to halt ELEVIDYS shipments for some patients - StreetInsider
Sarepta Says Another Patient Died After Receiving Gene Therapy - Bloomberg
FDA Shuts Down Sarepta's Distribution of Gene Therapy Elevidys Following Patient Deaths - NeurologyLive
Sarepta Therapeutics Provides Statement on ELEVIDYS - Sarepta Therapeutics
Gene-therapy company to eliminate 21 Durham employees as part of major restructuring - WRAL.com
HHS Says FDA Requests Sarepta Therapeutics Suspend Distribution Of Elevidys And Places Clinical Trials On Hold For Multiple Gene Therapy Products Following 3 Deaths - TradingView
FDA prepares to ask Sarepta Therapeutics to stop all shipments of Duchenne muscular dystrophy therapy - The Boston Globe
SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
Exclusive-US FDA to ask Sarepta to stop shipments of gene therapy Elevidys, source says - MarketScreener
Exclusive: US FDA to ask Sarepta to stop shipments of gene therapy Elevidys, source says - Reuters
Sarepta Therapeutics laying off 80 employees in Ohio - WTTE
Major biotech stock tumbles 35 percent after major rare disease setback - TheStreet
Sarepta Crashes Almost 40% On A Damning Move From The FDA - Investor's Business Daily
Elevidys' future said to be on ice after Sarepta reports patient death from separate gene therapy - FirstWord Pharma
FDA to Ask Sarepta to Stop Shipping Muscular Dystrophy Drug Elevidys - The New York Times
SRPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Investors Urged to Contact Levi & Korsinsky for Information Before August 25, 2025Sarepta Therapeutics, Inc. (SRPT) - TradingView
Sarepta Stock (SRPT) Crashes 37% as FDA Scrutiny Mounts Over Gene Therapy Deaths - TipRanks
SRPT BREAKING NEWS: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Announces Third Death -- Contact BFA Law by the August 25 Class Action Deadline - GlobeNewswire
SRPT BREAKING NEWS: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Announces Third Death -- Contact BFA Law by the August 25 Class Action Deadline - GlobeNewswire Inc.
Baird downgrades Sarepta Therapeutics stock rating on Elevidys safety concerns - Investing.com
FDA mulls Elevidys market withdrawal following 3rd death after Sarepta gene therapy - Fierce Pharma
Sarepta shares plunge 30% as future of its gene therapy appears at risk - MSN
Sarepta Shares Crash on Report That FDA Will Ask It to Stop Shipping Drug - Barron's
Sarepta Craters as FDA Considers Requesting Halt to Elevidys Shipments - BioSpace
FDA to ask Sarepta to stop shipping Duchenne gene therapy - BioPharma Dive
Sarepta: Despite Restructuring, Downgrading To Sell After Latest Developments (SRPT) - Seeking Alpha
Baird Downgrades Sarepta Therapeutics (SRPT) to Neutral, 'Transparency Issues and Elevidys Uncertainty' - StreetInsider
Strategic Restructure and ELEVIDYS Label Update Call (NASDAQ:SRPT) - Seeking Alpha
Sarepta falls as FDA mulls Elevidys' future (update) (SRPT) - Seeking Alpha
FDA to request Sarepta Therapeutics halt shipments of Duchenne gene therapy - STAT
Finanzdaten der Sarepta Therapeutics Inc-Aktie (SRPT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.59%
0.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):